Effectiveness and safety of carbon ion radiotherapy for stage III non-small cell lung cancer: a single-center retrospective study - Takeaways - MDSpire

Effectiveness and safety of carbon ion radiotherapy for stage III non-small cell lung cancer: a single-center retrospective study

  • By

  • Xiaoli Zhao

  • Bole Wang

  • Yihe Zhang

  • Pengqing Li

  • Xuexue Liang

  • Qinli Gong

  • Ling Tian

  • Tianyan Qin

  • Xuelian Chen

  • Zhenglin Li

  • Peng Nie

  • Yanshan Zhang

  • Yancheng Ye

  • June 30, 2026

  • 0 min

Share

  • 1

    A retrospective analysis evaluated 82 patients with stage III non-small cell lung cancer treated with carbon ion radiotherapy from March 2020 to March 2024.

  • 2

    The 1-year overall survival, progression-free survival, and local control rates were 85.4%, 79.8%, and 95.3%, respectively.

  • 3

    Adverse events included grade 1 radiation pneumonitis in 6.1% of patients and grade 1 radiation esophagitis in 43.9%.

  • 4

    CIRT combined with immunotherapy was identified as an independent favorable factor for improving overall survival.

  • 5

    The study suggests that CIRT can provide significant survival benefits for stage III NSCLC, with manageable adverse reactions.

Original Source(s)

Effectiveness and safety of carbon ion radiotherapy for stage III non-small cell lung cancer: a single-center retrospective study

  • by Xiaoli Zhao, Bole Wang, Yihe Zhang, Pengqing Li, Xuexue Liang, Qinli Gong, Ling Tian, Tianyan Qin, Xuelian Chen, Zhenglin Li, Peng Nie, Yanshan Zhang, Yancheng Ye

  • June 30, 2026

Related Content

Mixed adenoneuroendocrine carcinoma of the gallbladder: a case report and literature review

Advances in the prevention and treatment of radiation-induced brain necrosis: a narrative review

Bladder metastasis from gastric cancer presenting as acute post-renal obstruction during immunotherapy: a case report